Review
Pathology
Sulieman Ibraheem Shelash Al-Hawary, Ebraheem Abdu Musad Saleh, Nodirjon Akhmetovich Mamajanov, Nataliya S. Gilmanova, Hashem O. Alsaab, Adel Alghamdi, Shakeel Ahmed Ansari, Ahmed Hussien Radie Alawady, Ali Hashiem Alsaalamy, Ahmed Jaber Ibrahim
Summary: According to the International Agency for Research on Cancer, breast cancer is more common than lung cancer globally. By 2040, mortality from breast cancer will rise by 50% and 40%, respectively. Despite advances in chemotherapy, endocrine therapy, and HER2-targeted therapy, breast cancer metastases and recurrences remain challenging to treat.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Review
Immunology
Si-Yuan Zhu, Ke-Da Yu
Summary: Breast cancer is the most commonly diagnosed cancer worldwide, with relapse and metastasis posing significant challenges. Innovative therapeutic strategies, such as cancer vaccines, are needed to address these challenges. Although current results have been disappointing, recent studies suggest the potential of combining vaccines with other treatments for breast cancer.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Fatemeh Zahedipour, Seyede Atefe Hosseini, Mojgan Astaneh, Prashant Kesharwani, Mahmoud Reza Jaafari, Amirhossein Sahebkar
Summary: This systematic review aims to comprehensively evaluate the therapeutic efficacy, immune response, survival rate, and side effects of VEGF/VEGF receptor-based peptide vaccines. VEGF/VEGFR2 peptide vaccines were found to be safe and effective in inducing anti-tumor immune responses, while showing moderate clinical benefit. Further clinical trials are needed to fully evaluate their clinical effects and the correlation between immune response induction and clinical outcomes.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Immunology
Samantha J. Paston, Victoria A. Brentville, Peter Symonds, Lindy G. Durrant
Summary: Vaccination has had a significant impact in preventing infectious diseases, but the development of therapeutic cancer vaccines has been challenging.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Mary E. Carter, Andre Koch, Ulrich M. Lauer, Andreas D. Hartkopf
Summary: Breast cancer is the second most common type of cancer globally, with oncolytic viruses showing promise as a new treatment approach. Several types of oncolytic viruses have been studied in clinical trials, demonstrating clinical activity in patients with different advanced tumors including breast cancer. Further research is needed to explore optimal treatment strategies for breast cancer using oncolytic viruses.
FRONTIERS IN ONCOLOGY
(2021)
Review
Immunology
Maryam Abbaspour, Vajihe Akbari
Summary: This paper summarizes and discusses the recent development of therapeutic vaccines for breast cancer, including the use of specific breast cancer cellular antigens, antigen selection, and probable causes for their insufficient effectiveness.
EXPERT REVIEW OF VACCINES
(2022)
Article
Oncology
Olga Kantor, Cecilia Chang, Katharine Yao, Judy Boughey, Christina Roland, Amanda B. Francescatti, Sarah Blair, Diana Dickson Witmer, Kelly K. Hunt, Heidi Nelson, Anna Weiss, Tawakalitu Oseni
Summary: The study aimed to examine the uptake of clinical trials that have changed axillary management in breast cancer patients at minority-serving hospitals (MSH) and non-MSH cancer centers. Results show that, despite adjusting for social determinants of health, there was no significant difference in the uptake of three landmark clinical trials of axillary management in breast cancer between MSH and non-MSH centers.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Chemistry, Medicinal
Muhammad Luqman Nordin, Ahmad Khusairi Azemi, Abu Hassan Nordin, Walid Nabgan, Pei Yuen Ng, Khatijah Yusoff, Nadiah Abu, Kue Peng Lim, Zainul Amiruddin Zakaria, Noraznawati Ismail, Fazren Azmi
Summary: Breast cancer is the second-leading cancer globally, and immunotherapy via vaccine has gained attention for its specific and targeted immune cell activity against the disease. Peptide-based vaccines, despite their vulnerabilities, can be customized and improved with carriers to induce a specific immune response. Nanotechnology advancements allow the incorporation of other components into peptide-based vaccines, modulating the immune response against breast cancer.
Review
Oncology
Edoardo Crimini, Matteo Repetto, Philippe Aftimos, Andrea Botticelli, Paolo Marchetti, Giuseppe Curigliano
Summary: This review presents the most important molecular targets in breast cancer, classified according to their pathway and in accordance with ESCAT, assisting clinicians in making therapeutic decisions.
CANCER TREATMENT REVIEWS
(2021)
Article
Medicine, General & Internal
Katarzyna Szlezinger, Katarzyna Pogoda, Agnieszka Jagiello-Gruszfeld, Danuta Klosowska, Andrzej Gorski, Jan Borysowski
Summary: This study assessed the eligibility criteria in recent clinical trials for breast cancer. It found that many of these trials exclude large groups of patients, especially older adults, individuals with comorbidities, and those with poor performance status. Therefore, careful modification of these criteria is needed to evaluate the benefits and harms of investigational treatments in patients with characteristics commonly encountered in clinical practice.
Article
Pharmacology & Pharmacy
Parvin Zamani, Mohammad Mashreghi, Mahere Rezazade Bazaz, Farshad Mirzavi, Mehdi Barati, Fatemeh Zahedipour, Mahmoud Reza Jaafari
Summary: The study showed that a liposomal-based peptide vaccine containing AE36, PADRE, and MPL could induce significant immune responses and potential prophylactic vaccine candidacy in a mouse model of breast cancer.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Arsalan Hamid, Markus S. Anker, John C. Ruckdeschel, Muhammad Shahzeb Khan, Arsal Tharwani, Adebamike A. Oshunbade, Rodney K. Kipchumba, Samuel C. Thigpen, Stefan D. Anker, Gregg C. Fonarow, Michael E. Hall, Javed Butler
Summary: The study found that patients with cardiovascular conditions or prevalent cardiovascular disease were significantly underrepresented in contemporary later-phase breast cancer trials, and cardiovascular safety was not routinely monitored in these trials.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Oncology
Kelsey L. Corrigan, Ramez Kouzy, Joseph Abi Jaoude, Roshal R. Patel, Rachel M. Layman, Sharon H. Giordano, Wendy A. Woodward, Benjamin D. Smith, Simona F. Shaitelman, Ethan B. Ludmir
Summary: The study found that about 77.1% of breast cancer RCTs include PMBC patients. Lower rates of PMBC inclusion were seen in trials that studied HR+/HER2- patients and in trials that randomized or mandated ET, while trials studying chemotherapy were associated with inclusion of PMBC patients.
Article
Oncology
Aakash Desai, Justin F. Gainor, Aparna Hegde, Alison M. Schram, Guiseppe Curigiliano, Sumanta Pal, Stephen V. Liu, Balazs Halmos, Roman Groisberg, Enrique Grande, Tomislav Dragovich, Marc Matrana, Neeraj Agarwal, Sant Chawla, Shumei Kato, Gilberto Morgan, Pashtoon M. Kasi, Benjamin Solomon, Herbert H. Loong, Haeseong Park, Toni K. Choueiri, Ishwaria M. Subbiah, Naveen Pemmaraju, Vivek Subbiah
Summary: The rapid development of COVID-19 vaccines has provided new hope of mitigating the disease, and it is necessary to prioritize cancer patients, including those participating in oncology clinical trials, for vaccination. Data on the safety, tolerability and efficacy of the vaccines in patients with cancer are currently limited, but the benefits of vaccination are likely to far outweigh the risks of adverse events.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Sandeep Pallerla, Ata ur Rahman Mohammed Abdul, Jill Comeau, Seetharama Jois
Summary: Breast cancer is a major cause of death in women, with improvements in targeted therapies but still facing issues of resistance and limitations. Vaccine therapy introduces antigens to activate the immune system, providing longer-term immune memory to prevent cancer relapse.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)